AlzeCure publishes its interim report for January – March 2026

“During the first quarter of 2026, our focus was on preparing the Phase II study in Alzheimer’s patients with NeuroRestore ACD856, for which we were awarded a grant of EUR 2.5 million from the European Innovation Council (EIC). In addition, we successfully advanced the Phase Ib clinical trial with ACD856, further expanding the therapeutic dose window to increase our opportunities to address multiple indications. During the quarter, we also continued preparing for a potential registrational study for the pain project Painless ACD440. In February, ACD440 was granted orphan drug designation by the European Medicines Agency. We also remained active in business development at international conferences and published new data from our NeuroRestore project at the world‑leading Alzheimer’s conference AD/PD 2026, which was held in Copenhagen in March.”

Martin Jönsson, CEO

Financial information for January – March 2026, Group
Figures in parentheses refer to the corresponding period of the previous year.

• Net sales during the period totaled SEK 0 thousand (0).
• Earnings for the period totaled SEK -21,695 thousand (-10,130).
• Earnings per share, basic, totaled SEK -0.19 (-0.11).
• Cash flow from operating activities totaled SEK -17,089 thousand (SEK -10,416).
• Total assets at the end of the period amounted to SEK 40,806 thousand (29,252).
• Cash and cash equivalents at the end of the period totaled SEK 32,967 thousand (20,819).

AlzeCure Pharma AB (publ) acquired a newly formed subsidiary at the end of September 2025, which is currently dormant, to prepare the Group structure for any potential future needs. No operations have been conducted in the subsidiary; all business activities are carried out by the parent company, AlzeCure Pharma AB (publ).

Significant events during the period January – March 2026

• In February 2026, the pain project ACD440 was granted orphan drug designation in Europe by the EMA.
• AlzeCure presented new preclinical data concerning NeuroRestore ACD856 at the AD/PD Alzheimer’s conference in mid-March.

Significant events after the end of the period

• In April, the company announces that the last participant has completed treatment in AlzeCure's clinical phase Ib study with NeuroRestore ACD856.
• In April, the board of directors, supported by the authorization granted by the Annual General Meeting on May 14, 2025, decides to carry out a rights issue of approximately SEK 30.1 million. The issue is, free of charge, 100 percent secured.

The full report is attached as PDF and is available on the company’s website: www.alzecurepharma.com/en/section/investors/financial-reports/